We’re just getting started.

GreenLight’s 13+ years of scientific progress has led us up to a few key successes.

Platform for mRNA

GreenLight’s platform, developed through 13 years of research and technology, is protected by foundational patents. Our process know-how, and the technology we developed to produce double-stranded RNA at metric-ton scale, can be leveraged and transformed, using our technical agility, for our mRNA platform. 

7+ agricultural products in development

…with an addressable market of $6b that we plan to launch by 2026.

Demonstrated control of fungal pathogens

Control of fungal pathogens using double-stranded RNA has been demonstrated in field testing for the first time. This addresses the number one cause of food rotting. Based on this data, we have made the decision to move from discovery to development of a product to address the number one cause of food rotting. In the overall agricultural space, this represents an enormous market.

Progress for bees

Higher brood and health scores on bee colonies for our varroa mite treatment, compared to chemical controls with 2 and 8g/l application. The data from our trials to treats varroa mite infestation in beehives supports our progress toward commercialization and demonstrates that that we can acquire a product, improve upon it, and then move toward having a real-world solution that protects bees, beekeepers, and pollination-dependent crops.

A Covid-19 vaccine

We have witnessed promising antibody response and cell-mediated immunity for our GreenLight Covid-19 vaccine candidates in mice. The data indicates feasibility of initiating clinical trials in Africa for our vaccine candidate.

Bill & Melinda Gates milestone reached

Our RNA-based candidate is designed to deliver a healthy copy of the gene to stem cells. Our concept of simple injections of mRNA/lipid nanoparticle formulations is a treatment method we are actively researching with a Bill and Melinda Gates Foundation grant to develop gene therapies to treat sickle cell anemia. It’s time to move to the next phase of research.

To find out more, click here.